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Piecewise function parameters as responses of the design 
of experiment in the development of a pulsatile release 
chronopharmaceutical system
The aim of this work was to develop a pulsatile release sys-
tem with metoprolol for chronotherapeutical use by coating 
swellable mini-tablets with Eudragit RS. To study the influ-
ence of the formulation factors (amount of coating polymer, 
plasticizer percentage in film coating and swelling agent 
percentage in mini-tablets), a Box-Behnken design of experi-
ment (DoE) was used. To evaluate the influence of the stud-
ied factors on the sigmoid shape of the dissolution profile, 
piecewise function parameters were used as the responses 
of DoE. The results show that higher concentrations of coat-
ing polymer and higher concentrations of plasticizer poly-
mer led to a thicker and more elastic polymeric film, which 
led to a delay in drug release. Using the parameters of the 
piecewise function as DoE responses, an optimum formula-
tion with a sigmoid shape dissolution profile and a 2.5-h lag 
time followed by rapid drug release were obtained. 
Keywords: pulsatile release, chronopharmaceutical system, 
piecewise function, design of experiment, Eudragit RS, 
metoprolol
Chronotherapy is the delivery of a drug at the right concentration to the right targeted 
tissues at the right time to meet the biological rhythm-determined needs (1–3). Blood pres-
sure is characterized by predictable changes over 24 hours in synchrony with the rest–ac-
tivity cycle. The rate of blood pressure rise at the commencement of diurnal activity is a 
predictor of the risk of morning stroke and acute coronary syndrome, and it is also hypoth-
esized to be a trigger for myocardial infarction at that time of the day (4, 5). Metoprolol is 
a cardioselective beta-blocker used in the management of hypertension, angina pectoris 
cardiac arrhythmias, myocardial infarction and heart failure. Because of its antihyperten-
sive action, a formulation suitable for chronotherapy could be important for the treatment 
of hypertension (6, 7).
The values of blood pressure vary throughout the day, especially in the morning 
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the necessary quantity of metoprolol in the blood before waking up and would poten-
tially control the increase in blood pressure. The patient would take the chronopharma-
ceutical formulation with metoprolol at bedtime; after a lag time of 2.5-3 hours, followed 
by a rapid drug release (1-1.5 hours), the needed metoprolol quantity would be in the blood 
stream before the early morning hours when blood pressure is most likely to increase, thus 
providing the necessary control (8, 9). 
Chronotherapy can be attained with pulsatile drug delivery systems. Ideally, a pulsa-
tile release system releases the drug rapidly and completely after a predefined lag time of 
no drug release. The mechanism of reservoir-type pulsatile systems is based on drug re-
lease from a drug core (tablet or capsule) after the rupture of the surrounding polymer 
coating layer caused by the pressure built-up within the system. The pressure necessary 
to break the coating layer can be achieved with the aid of gas-producing effervescent ex-
cipients or by increasing the inner osmotic pressure using swelling agents such as cellu-
lose ethers, polysaccharides or superdisintegrants (10–12).
In vitro drug dissolution has been recognized as an important tool in drug develop-
ment. Several kinetic equations describe drug release from immediate and modified oral 
dosage forms (13, 14). Quantitative interpretation of the values obtained from in vitro dis-
solution studies is facilitated by the use of a mathematical equation that translates the 
dissolution profile into parameters relating to the pharmaceutical characteristics of the 
dosage form. The drug release profile from a pulsatile release chronopharmaceutical sys-
tem is characterized by a period of low or no drug release (lag time), followed by a rapid 
drug release period (pulse release) and then a period after most of the drug has been re-
leased. The ideal shape of such a profile is sigmoid and has two turning points: (i) the end 
of the lag time period – the beginning of the rapid release period, and (ii) the end of the 
rapid release period (Fig. 1a) (15). 
The piecewise function is a function defined by multiple sub-functions, each sub-
function applying to a certain interval (domain) of the main function.  Piecewise three 
segment linear function is a linear function that consists of three segments and two 
Fig. 1. Drug release from pulsatile drug delivery systems. a) ideal sigmoid release, b) graphical shape of 
piecewise three segment linear function; y2 – drug released at the first turning point; y3 – drug released 
at the second turning point; t1 – time at the first turning point; t2 – time at the second turning point.
a)                                                                                b)
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Where:  y1 – minimum value; y2 – first turning point; y3 – second turning point; 
y4 – maximum value; t1 – time at the first turning point; 
t2 – time at the second turning point.
The in vitro dissolution profiles of a pulsatile release chronopharmaceutical system 
can be described by the piecewise three segment linear function, where the first segment 
is the lag time period when the drug is not released or the amount of drug release is low, 
the second segment is the period of rapid drug release, the third segment is the period 
after more than 80 % of the drug has been released, and the turning points are the points 
of the start and the end of the rapid release period. Each turning point is characterized by 
two parameters, whose values can be used for the quantitative characterization of the re-
lease profile of the pulsatile chronopharmaceutical system.
Many papers have reported the development of pulsatile chronopharmaceutical 
systems (1, 7, 9, 10), in some of which design of experiments was used (2, 13, 20), but so 
far the use of piecewise function parameters for characterization of the dissolution pro-
file shape has not been reported. The advantage of using piecewise function is precise 
characterization of the pulsatile release profile by two turning points of the sigmoid 
shape. Further, each turning point is numerically characterized by two parameters that 
may be the responses of an experimental design. Thus, in the development of a pulsatile 
drug delivery system using an experimental design, the parameters of piecewise func-
tion may have the target value to obtain the desired sigmoid shape of the dissolution 
release profile.  
In a previous experimental paper, we established that a suitable film forming poly-
mer for obtaining pulsatile release from film-coated swellable metoprolol cores was Eu-
dragit RS, an insoluble, but slowly permeable polymer (17). From these reservoir-type 
pulsatile systems, rapid release of the drug from the core after a lag time period (the 
moment when the polymeric film breaks) can be modulated by modifying the thickness 
(amount) of the film coating, the elasticity of the film coating and the inner pressure 
generated by core swelling.
The aim of this work was to use a Box Behnken experimental design and piecewise 
three segment linear function parameters as dependent variables (responses) of the ex-
perimental design to study the influence of the film coating polymer (Eudragit RS) per-
centage, the plasticizer in film coating (triethylcitrate) percentage and the swelling agent 
in mini-tablet cores (sodium starch glycolate) percentage on the drug release profile in 
order to develop a mini-tablet type pulsatile release chronopharmaceutical system with an 
optimized drug release profile. 
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Metoprolol tartrate (Microsin, Romania) was chosen as a model drug. Lactose mono-
hydrate 800 Mesh (HMS, Holland), microcrystalline cellulose – PH 102 (JRS Pharma, Ger-
many), silicon dioxide – Aerosil (BASF, Germany), talcum (S&D Chemicals, UK) and mag-
nesium stearate (Merck, Germany) were used as excipients in the core tablets. 
Polyvinylpyrolidone K25 (Merck, Germany) was used as a binder in the granulation step. 
Sodium starch glycolate (JRS Pharma, Germany) was used as a swelling agent in the core 
tablets. Mini-tablets were coated with different amounts of the insoluble, but slowly per-
meable Eudragit RS 30D (Rohm Pharma, Germany) film coating polymer. Triethylcitrate 
(Merck, Germany) was added as a plasticizer and simeticone (Colorcon, UK) was added as 
an anti-foaming agent to the film coat. 
Apparatus
A fluid bed device Strea 1 (Aeromatic A.G., Switzerland) was used to obtain the gran-
ules and to coat mini-tablets. A DIN sieve set (VEB MLW, Germany) and a mass volumetric 









Independent variables (formulation factors)
x1 = film forming polymer percentage (Eudragit RS) 5 11 17
x2 = swelling agent percentage (sodium starch glycolate) 10 15 20
x3 = plasticizer percentage (triethylcitrate) 8 12 16
Dependent variables (responses)
y1   = cumulative % of metoprolol released after 1.0 h
y2 = cumulative % of metoprolol released after 2.0 h
y3   = cumulative % of metoprolol released after 2.5 h
y4   = cumulative % of metoprolol released after 3.0 h
y5   = cumulative % of metoprolol released after 3.5 h
y6 = cumulative % of metoprolol released after 4.0 h
y7 = cumulative % of metoprolol released after 5.0 h
y8 = cumulative % of metoprolol released after 7.0 h
y9 = c2  – concentration at the first turning point
y10 = t1 – time at the first turning point
y11 = c3 – concentration at the second turning point
y12 = t2 – time at the second turning point
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test apparatus SVM (Erweka, Germany) were used for particle measurements and for the 
Carr Index and Haussner ratio determination. The cores were obtained using a tablet press 
EK-0 (Korsch, Germany) and their hardness was tested using a Monsanto tablet hardness 
test apparatus (Monsanto, Italy). Dissolution studies were done in a PT-DT7 dissolution 
apparatus (PharmaTest, Germany) and the in vitro dug assay was done using a UV-Vis 
V530 spectrophotometer (Jasco, Japan).
Design of Experiment (DoE)
A Box Behnken design of experiment with three factors and three levels was used 
to study the influence of formulation variables on the drug release profiles and piece-
wise equation parameters. The studied formulation factors (independent variables) were 
the percentage of polymeric film used for coating (Eudragit RS 30D) – x1, percentage of 
the swelling core agent (sodium starch glycolate) – x2, and percentage of the polymeric 
film plasticizer (triethylcitrate) – x3. Dependent variables (responses) were the cumula-
tive percentage of drug release at different time intervals and the piecewise function 
parameters. The levels of variation of independent variables and the dependent vari-
ables are shown in Table I.
The construction of the design of experiment, computation of coefficients, statistical 
parameters and fitting of the experimental data in order to assess the results were per-
formed using the Modde 10.0 software, Umetrics, Sweden. The data fit was done using the 
Partial Least Squares (PLS) method.
Granule preparation and evaluation 
In order to obtain metoprolol mini-tablets as cores (25 mg metoprolol in 75 mg tablets, 
or 33.34 %), a preliminary granulation step was necessary. Metoprolol tartrate was mixed 
with various ratios of sodium starch glycolate (10, 15 and 20 %) and monohydrate lactose 
(18.99, 13.99 and 8.99 %). The mixtures were transformed into granules using a 10 % poly-
vinylpyrrolidone aqueous solution as binder in a Strea 1 fluid bed device (Aeromatic, Swit-
zerland). The granulation process was done using the optimized method previously re-
ported (18).
Before tableting, the granules were physically characterized in order to assess the 
flowability and compressibility properties. To evaluate the Carr index and Hausner ratio, 
the untapped and tapped densities of the granules were determined according to the well-
known methods described in the European Pharmacopoeia (19). 
In order to evaluate the size and size distribution, the granules were sieved using a 
set of sieves with different apertures (100, 200, 300, 400, 500, and 600 mm), and the granules 
mean diameter (Md) and granules poly-dispersion index (P.I.) were calculated.  
The mean particle diameter was calculated using the equation: 
 = ± ∑ i in xMd
N
 (Eq. 2)
Md – granule mean diameter, 
N – total frequency (in this case 100 %).
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P.I. was measured with the equation: 
 SD. . 100= ± ×P I
Md
 (Eq. 3)
Md – granule mean diameter, 
SD – standard deviation.
Tablet preparation and tablet coating
Microcrystalline cellulose (33.3 %), magnesium stearate (1 %) and silicon dioxide (1 %) 
were added to the obtained granules and were compressed using an eccentric press 
(Korsch EK 0, Germany) equipped with a set of 5 mm biconvex punches. The machine was 
configured to obtain 75-mg tablets with a crushing strength of 5–9 kg. After the prepara-
tion, the tablets were analyzed according to the well-known pharmaceutical procedures 
from the European Pharmacopeia (17).
The tablets were finally coated in a Wurster configuration fluid bed device (Strea 1 – 
Aeromatic GEA, Switzerland) with different amounts of Eudragit RS. The composition of 
the coating suspension was: Eudragit RS 30D (5-11-17 %, according to the experimental 
design matrix, Table II), triethylcitrate (8-12-19 %, according to the experimental design 
matrix, Table II), talcum (30 %), titanium dioxide (5 %) and pigment (3 %). To prepare the 
coating suspension, triethylcitrate was first dispersed in water, then talcum, titanium di-
oxide and pigment were suspended in water and homogenized (Ultra Turrax); this suspen-
sion was poured into the Eudragit RS 30D dispersion under gentle mixing; the obtained 
mixture was homogenized for 40 minutes before use and then passed through a 0.25-mm 
sieve; the final mixture containing 22 % solid particles was processed by continuous gentle 
stirring during the coating process. Technological parameters during the coating process 
were: gun nozzle 0.8 mm, atomizing air pressure 3.6 atm, spraying rate 10 g/min, inlet air 
temperature 34–42 °C and outlet air temperature 30–35 °C, fan air 3.6 m3/min.
Dissolution studies
In vitro dissolution studies were performed in a PharmaTest PT-DT7 device, equipped 
with paddles (European Pharmacopoeia apparatus 1), employing a rotation speed of 50 
rpm. The dissolution medium was 500 mL phosphate buffer (pH = 6.8) at 37 °C. Four tablets 
were immersed in the dissolution medium, each containing approximately 25 mg meto-
prolol (100 mg per dissolution vessel – the usual daily dosage of metoprolol). Samples were 
taken at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 and 7 h. Each 5-mL sample was immedi-
ately passed through a 0.45-μm filter and replaced with the same volume of fresh dissolu-
tion medium in order to maintain a constant volume throughout the experiment. The 
samples were analyzed by UV spectrometry at 275 nm using a validated method. The fol-
lowing parameters were subjected to validation: specificity, linearity, accuracy, precision 
and stability of metoprolol in dissolution medium). Three determinations were performed 
for each formulation and the mean and standard deviation were calculated at each dissolu-
tion point.  
To evaluate the dissolution profile, a piecewise three segment linear function was 
used (Eq. 1). This defines the cumulative expression of fractionized drug release in time as 
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a time function modelled by three separate equations, representing three linear segments 
united at their ends. The three segments represent three regions: the time before, during 
and after rapid release. The first turning point represents the beginning of drug release, 
after the lag time, and the second turning point represents the end of release (14, 20, 21). 
Piecewise function parameters were introduced as responses (dependent variables) of the 
experimental design together with the amount of drug released at defined periods of time 
(Table I, dependent variables y9-y12). 
RESULTS AND DISCUSSIONS
Influence of formulation factors on granule and tablet characteristics 
Mass uniformity of mini-tablets can be assured if the powders for tableting fill the die 
uniformly. This can be done only if granules have good flow properties and low size dis-
tribution variability. According to the obtained results, all the granules had good flow 
properties, irrespective of the percentage of sodium starch glycolate used. The Carr index 
was between 5.3 and 11.18, corresponding to an excellent flow (free granule flow). Extreme 
values appeared when 20 % sodium starch glycolate was used. The Hausner ratio had very 
low variability, with values between 1.07 and 1.13, all lower than 1.2, corresponding to an 
easy flow. The mean particle diameter had values between 234.77 and 313.4 μm, and the 
variation coefficient had values between 39.239 and 49.578, so there were no big differ-
ences between particle sizes. 
As mini-tablets will later be coated in a fluid bed, they should have very good phar-
maceutical properties. All the formulations were analyzed according to the European 
Pharmacopoeia methods for average mass and mass uniformity, resistance to crushing, 
disintegration time, and friability. According to the obtained results, all the prepared for-
mulations of metoprolol mini-tablets showed low weight variability (lower than 5 %), de-
sirable drug content (25.15 mg/tablets), good resistance to crushing (between 40 and 50 N), 
good disintegration time (maximum 3 minutes) and very good friability (0 %).
The different amounts of sodium starch glycolate used did not influence the pharma-
ceutical properties of the granules (flow properties, particle mean diameter and variation 
coefficient) and the tablets (mass uniformity, resistance to crushing, time of disintegration 
and friability).
Thus, all the mini-tablet batches had very good pharmaceutical properties, according 
to the European Pharmacopeia requirements, and were suitable for coating in the fluid bed 
device.
Design of experiment analysis. Summary of fit
The results matrix is shown in Table II. The results show that the amount of metopro-
lol released (y1-y12 responses) depended on the formulation factors studied in the experi-
mental design. 
To check the experimental design validity, the following statistical parameters were 
determined: R2, Q2 and ANOVA. R2 represents the fraction of variation of the response 
explained by the model while Q2 represents the fraction of variation of the response that 
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can be predicted by the model. Both R2 and Q2 values are numbers (usually between 0 and 
1) and values close to 1 indicate a good model with excellent predictive power (22). The 
values of R2 were over 0.8 for all results, except for y1, when it was close to 0.8. The values 
of Q2 were over 0.6 for y2, y3, y4, y5, y6, y7, y8, y10 and y11, and between 0.1 and 0.6 for y1, y9 
Table II. Matrix of the design of experiment and the results matrix
Experiment 
name x1 x2 x3 y1 y2 y3 y4
N1 5 10 12 8.38 45.17 56.74 66.88
N2 17 10 12 1.87 2.01 1.98 2.55
N3 5 20 12 53.86 97.89 98.04 100.55
N4 17 20 12 3.62 3.58 3.75 3.80
N5 5 15 8 81.21 95.90 97.36 99.92
N6 17 15 8 4.39 4.72 6.29 21.00
N7 5 15 16 3.74 5.19 7.13 10.44
N8 17 15 16 0.18 0.22 0.23 1.92
N9 11 10 8 12.22 39.45 82.08 93.61
N10 11 20 8 4.32 23.89 45.16 68.19
N11 11 10 16 2.68 1.47 1.55 1.24
N12 11 20 16 1.85 2.13 1.78 1.89
N13 11 15 12 0.69 0.92 0.92 4.87
N14 11 15 12 1.64 2.02 1.97 2.65
y5 y6 y7 y8 y9 y10 y11 y12
N1 76.79 80.73 93.58 101.53 8.52 1.02 77.21 3.22
N2 2.35 2.39 2.71 3.37 1.86 6.23 2.97 6.91
N3 100.52 99.40 99.47 95.70 35.71 0.28 100.5 2.14
N4 3.69 3.98 5.20 10.12 1.35 6.11 4.75 6.84
N5 99.76 99.54 100.43 98.75 10.17 0.33 96.37 1.11
N6 45.72 84.41 102.35 105.25 6.67 2.81 99.55 4.27
N7 14.39 18.68 26.97 43.78 7.32 2.69 39.92 6.42
N8 0.90 0.12 1.14 0.47 0.38 7.21 1.06 7.08
N9 97.75 101.62 101.54 100.54 13.02 0.81 97.11 2.67
N10 87.48 94.58 100.20 99.78 8.32 1.63 95.60 3.67
N11 1.31 1.23 1.52 1.75 1.76 7.00 1.17 7.56
N12 2.21 2.81 2.56 4.01 2.18 6.34 1.85 6.71
N13 2.01 2.96 1.83 2.33 1.07 6.78 3.15 7.03
N14 2.10 1.98 2.11 2.89 1.02 5.69 2.42 7.41
x1–x3 – independent variables (formulation factors), according to Table I.
y1–y12 – dependent variables (responses), according to Table I.
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and y12. ANOVA (analysis of variance) test results were good for almost all the answers 
studied: p for the model was less than 0.05 for all experiments; p for error was more than 
0.05 for all experiments. In conclusion, the results fit well with the y2, y3, y4, y5, y7, y8, and 
y11 responses and are satisfactory for the y1, y6, y9, y10 and y12 responses. 
Design of experiment analysis. In vitro drug release
Results of the in vitro release of metoprolol from the developed film coated mini-tablet 
type chronopharmaceutical system at different dissolution time intervals are shown in Fig. 
2. Equation coefficients, used to fit the experimental data with the chosen model, represent 
the influence of the studied factors and of the interaction between the studied factors on 
the responses. Values of the coefficients (x1, x2, and x3) are related to the effects of these 
variables on the corresponding responses (y1-y8). Coefficients with more than one factor 
term represent interaction terms, and coefficients with higher order terms indicate the 
quadratic (non-linear) nature of the relationship. Two and three dimensional plots were 
formed, based on the model, for the measured responses, in order to assess the chance of 
response surface. Also, the relationship between formulation factors (independent vari-
ables) and responses (dependent variables) can be further understood from these plots 
(23, 24).
The influence of formulation factors on the responses y1, y3, y5 and y8 is presented as 
scaled and centered coefficients and as the response surface plot in Fig. 3.  The same was 
found for other responses as the cumulative percent of metoprolol released (y2, y4, y6, y7). 
Results of the coefficient data analysis indicate that the amount of film forming poly-
mer (x1) and plasticizer (x3) had the strongest influence on drug release. The amount of film 
Fig. 2. Amount of metoprolol released at different dissolution time points. N1 – N14 – experiment name 
according to the experimental design matrix of (Table II).
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Fig. 3. Influence of the formulation factors on in vitro drug release (y1 – y8 responses). x1 – film forming 
polymer percentage (Eudragit RS); x2 – swelling agent percentage (sodium starch glycolate); x3 – plas-
ticizer percentage; y1, y3, y5, y8, – dependent variables (responses), according to Table I.
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forming polymer determines the thickness of the water permeable film. Water enters in-
side the nucleus making it swell because of the disintegrant (sodium starch glycolate), 
which leads to breaking of the polymer film. Addition of the plasticizer leads to formation 
of a more elastic film, which is more resistant to deformation, and thus harder to break. 
Drug release decreases with the increase of the amounts of film forming polymer and 
plasticizer. The more polymer is added, the thicker and harder to break is the film. The 
more plasticizer is added, the more elastic and harder to break is the film. The influence of 
these two factors increases with time, being smaller at the beginning of the process and 
then growing as time passes. This influence is small at the beginning because the nucleus 
swells independently of film thickness at the beginning of the release process. The influ-
ence grows with time because the breaking of the film depends on its thickness. Systems 
involving Eudragit L (25) or a blend of Eudragit RL/RS (26) as coating polymers exhibited 
a similar release mechanism.
However, the amount of sodium starch glycolate in the nucleus (x2) did not have a 
strong influence on the release. This can be explained by the fact that, even though differ-
ent amounts of sodium starch glycolate were added before the granulation step (10, 15, 20 
%), a large amount of microcrystalline cellulose was added after this step. This excipient 
has a good disintegration property; higher amounts of microcrystalline cellulose increased 
the disintegration force of the cores, leading to smaller differences between the mixtures 
with these amounts of sodium starch glycolate (27). Studies have shown that the lag time 
usually depends on the amount of sodium starch glycolate swelling polymer (28).
Design of experiment analysis. Piecewise equation parameters
In order to analyze the influence of formulation factors on drug release, the piecewise 
function parameters were introduced as responses (y9 – concentration at the first turning 
point, c2;  y10 – time at the first turning point, t1; y11 – concentration at the second turning 
point, c3; y12 – time at the second turning point, t2) in the experimental design. Coefficients 
of the equation used to fit the experimental data with the chosen model for profile release 
evaluation are presented as scaled and centered coefficients and as the response plot sur-
face in Fig. 4.
y9 represents the concentration at the first turning point (c2), which is the concentra-
tion at the beginning of drug release. When the polymer amount (x1) increases, the drug 
concentration at the first turning point decreases because the film obtained is thicker, 
harder to break, thus releasing a smaller amount of metoprolol. When the amount of plas-
ticizer (x3) increases, drug concentration at the first turning point decreases because the 
film obtained is more elastic, harder to break, thus releasing a smaller amount of metopro-
lol. It can be seen that the influence of these two formulation factors is not linear (x1x1 and 
x3x3 have different influence than x1 and x3); this can be seen in Fig. 4. y9. When using small 
amounts of polymer and plasticizer, a thin and brittle film is formed, easy to break, allow-
ing greater drug release. When using large amounts of polymer and small amounts of 
plasticizer, the film formed is thick, but easy to break because it is brittle, and when using 
small amounts of polymer and large amounts of plasticizer, the film formed is elastic, but 
thin and relatively easy to break. These are the three maximum points of drug concentra-
tion, which can be seen in Fig. 4. The amount of sodium starch glycolate (x2) has no impor-
tant influence on drug concentration at the first turning point. 
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Fig. 4. Influence of the formulation factors on piecewise parameters (y9–y12 responses).
x1 – film forming polymer percentage (Eudragit RS); x2 – swelling agent percentage (sodium starch 
glycolate); x3 – plasticizer percentage y9–c2, concentration at the first turning point; y10–t1, time at the 
first turning point; y11–c3, concentration at the second turningz point; y12–t2, time at the second tur-
ning point.
185
A. L. Vonica-Gligor et al.: Piecewise function parameters as responses of the design of experiment in the development of a pulsatile 
release chronopharmaceutical system, Acta Pharm. 66 (2016) 173–189.
 
y10 represents the time at the first turning point (t1), which is the moment when drug 
release begins. The time at the first turning point increases when the polymer amount in-
creases, and also when the plasticizer amount increases, because the film formed is thick or 
elastic, harder to break, delaying the drug release. It can be seen that the influence of these 
two formulation factors is not linear (x1x1 and x3x3 have a different influence than x1 and x3), 
as can be seen in Fig. 4. y10. There is a maximum of time at the first turning point, which is 
reached with a pretty large amount of polymer and with the maximum amount of plasti-
cizer, when the film is very thick and elastic, thus very hard to break. However, there is a 
small decrease in time when increasing the polymer amount to maximum. Sodium starch 
glycolate (x2) does not have a significant influence on time at the first turning point. 
y11 represents the concentration at the second turning point (c3), which is the maximum 
amount of drug released. When the polymer amount increases, the drug concentration at 
the second turning point decreases, because the film obtained is thicker, harder to break, 
thus releasing a smaller amount of metoprolol. When the amount of plasticizer increases, 
drug concentration at the second turning point decreases because the film obtained is more 
elastic, harder to break, thus releasing a smaller amount of metoprolol. It can be seen that the 
influence of these two formulation factors is not linear (x1x1 and x3x3 have a different influ-
ence than x1 and x3), as can be seen in Fig. 4. y11. When using small amounts of polymer and 
plasticizer, a thin and brittle film is formed, easy to break, allowing a greater drug release. 
When using large amounts of polymer and small amounts of plasticizer, the film formed is 
thick, but easy to break because it is brittle, and when using small amounts of polymer and 
large amounts of plasticizer, the film formed is elastic, but thin and relatively easy to break. 
These are the three maximum points of drug concentration, which can be seen in Fig. 4, 
surface response plot for y11 response. The amount of sodium starch glycolate (x2) has no 
important influence on drug concentration at the second turning point. 
y12 represents the time at the second turning point (t2), which is the moment when 
drug release reaches its maximum. The time at the second turning point increases when 
the polymer amount increases, and also when the plasticizer amount increases, because 
the film formed is thick or elastic, harder to break, delaying the moment when drug release 
ends. It can be seen that the influence of these two formulation factors is not linear (x1x1 
and x3x3 have a different influence than x1 and x3), and this can be seen in Fig. 4.y12. There 
is maximum time at the second turning point, which is reached with quite a large amount 
of polymer and with the maximum amount of plasticizer, when the film is very thick and 
elastic, thus very hard to break. However, there is a small decrease in time when increasing 
the polymer amount to the maximum. Sodium starch glycolate (x2) has no significant influ-
ence on the time at the second turning point. 
Optimum formula determination
For a pulsatile release chronopharmaceutical system, the dissolution profile of the 
experimental formulation should be compared with the ideal shape of a pulsatile release 
chronopharmaceutical system. This dissolution profile should have a sigmoid shape and 
two turning points (Fig. 1) and may be characterized by the parameters of the piecewise 
three segment linear function. 
In order to obtain such a dissolution profile, the requirements during the optimization 
step were to minimize the concentration at the first turning point (y9), to obtain a target of 
a minimum of 2.5 h for the time at the first turning point (y10), to maximize the concentra-
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tion at the second turning point (y11) and to minimize the time at the second turning point 
(y12). The optimum formula was calculated using the optimization module from Modde 
10.0 software. The level of the formulation factor for the optimum formula and the results 
of the optimum formula are shown in Table III. As seen in the last column of Table III, 
Table III. The optimum formula
Independent variables (formulation factors) Value level
x1 film forming polymer percentage (Eudragit RS) 13.21
x2 swelling agent percentage (sodium starch glycolate) 17.90
x3 plasticizer percentage (triethylcitrate) 8.00
Dependent variables (responses) Theoretical (predicted)
Practical 
(obtained)
y1 Cumulative % of metoprolol released after 1.0 h 4.040 4.13
y2 Cumulative % of metoprolol released after 2.0 h 8.050 8.26
y3 Cumulative % of metoprolol released after 2.5 h 11.111 20.68
y4 Cumulative % of metoprolol released after 3.0 h 23.385 45.17
y5 Cumulative % of metoprolol released after 3.5 h 46.513 97.23
y6 Cumulative % of metoprolol released after 4.0 h 89.246 100.00
y7 Cumulative % of metoprolol released after 5.0 h 90.274 100.73
y8 Cumulative % of metoprolol released after 7.0 h 101.263 99.83
y9 c2  – concentration at the first turning point 10.271 15.68
y10 t1 – time at the first turning point 2.699 2.53
y12 c3 – concentration at the second turning point 91.324 100.24
y13 t2 – time at the second turning point 3.941 3.53
Fig. 5. Drug release from the optimum formula in comparison with ideal pulsatile drug delivery.
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practical results obtained with the optimum formula are relatively close to the value pre-
dicted via experimental design. The ideal shape of the dissolution profile of a pulsatile 
release chronopharmaceutical system that has a lag time of 2.5 h followed by rapid release 
(maximum one h) is a sigmoid shape with two turning points at 2.5 and 3.5 h.  This profile 
is very similar to the dissolution profile of the optimum formulation (Fig. 5). 
The differences are only in the first part of the dissolution profile, but the percentage 
of drug released until the first turning point (2.5 h) is less than 10 %. Thus, using the opti-
mization module from Modde 10.0 software and piecewise function parameters as desired 
responses, the theoretical optimum formula was determined. Moreover, the dissolution 
profile of the optimal formulation has a sigmoid shape and a lag time of 2.5 h, followed by 
rapid drug release (in one h).
CONCLUSIONS
In this work, a Box Behnken DoE and piecewise three segment linear function param-
eters were used to develop a pulsatile release chronopharmaceutical system made up of 
mini-tablets with an increased capacity to swell, coated with an insoluble and slowly perme-
able but breakable polymeric film. Among the studied  factors (amount of coating polymer, 
percentage of core swelling agent and percentage of film plasticizer in polymeric film), two 
had a great influence on the release profiles: the amount of film forming polymer and the 
percentage of plasticizer added. Increasing the amount of film forming polymer leads to a 
thicker film, harder to break, leading to delayed drug release, or in case of large values, to 
stopping the drug release altogether. Similarly, increasing the percentage of plasticizer leads 
to formation of a more elastic film, less brittle, which causes a delay of drug release or even 
stopping of the drug release at higher concentrations. Using piecewise function parameters 
as DoE responses, an optimal formulation with a sigmoid shape dissolution release profile 
and a lag time of 2.5 h, followed by rapid drug release, was obtained. 
This work illustrates the possibility of modulating the drug release profile from the 
pulsatile release chronopharmaceutical system by using DoE to study the influence of 
formulation factors on the in vitro dissolution behavior and piecewise three segment linear 
function parameters as responses for dissolution release profile shape characterization. 
The results of this study may be exploited for further design of novel pulsatile drug release 
pharmaceutical systems.
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